Tag: Cancer
This study aimed to assess the survival and life quality evolution of patients subjected to surgical excision of oral and oropharyngeal squamous cell carcinoma. MATERIAL AND METHODS: Forty-seven patients treated at a Brazilian healthcare unit specialized in head and neck surgery between 2006 and 2007 were enrolled in the study. The gathering of data comprised reviewing hospital files and applying the University of Washington Quality of Life (UW-QOL) questionnaire previously and 1 year after the surgery. Comparative analysis used Poisson regression to assess factors associated with survival and a paired t-test to compare preoperative and 1-year postoperative QOL ratings. RESULTS: 1 year after surgery, 7 patients were not found (dropout of the cohort); 15 had died and 25 fulfilled the UW-QOL…
Source: MedWorm: Oral Cancer
Tags: 1year, Cancer, followup, Life, Oral, oropharyngeal, patients, quality, resection, survival, tumor
Posted in Treatment | No Comments »
Long-term oral bisphosphonates may double risk of oesophageal cancerRelated items from OnMedicaBisphosphonate use does not raise cancer riskMortality higher if using paroxetine and tamoxifenNew osteoporosis risk scores highly effectiveFalls prevention services are not evidence-basedBenefits of statins ’still outweigh risks’ (Source: OnMedica Latest News)
Source: MedWorm: Oral Cancer
Tags: Bisphosphonates, Cancer, double, risk
Posted in Treatment | No Comments »
OXFORD, England, Sept. 3 (UPI) — Long-term use of oral bisphosphonates — used to prevent bone loss — may double the risk of developing esophageal cancer, researchers in Britain say.
Osteoporosis – Esophageal cancer – Health – Cancer – England (Source: Health News – UPI.com)
Source: MedWorm: Oral Cancer
Tags: Cancer, Drug, linked, Osteoporosis
Posted in Treatment | No Comments »
As a new study reports a link, in direct contrast to a previous recent study, experts emphasize that patients need to be reminded about how to take these drugs. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: MedWorm: Oral Cancer
Tags: About, Bisphosphonates, Cancer, esophageal, Face, linked, Oral
Posted in Treatment | No Comments »
People who take oral bisphosphonates for osteoporosis over five years may be doubling their risk of developing oesophageal cancer, according to a UK study published online in the BMJ. (Source: Nursing Times Breaking News)
Source: MedWorm: Oral Cancer
Tags: 'doubles, Cancer, medication, Osteoporosis, risk
Posted in Treatment | No Comments »
People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing esophageal cancer (cancer of the gullet), according to a new study. (Source: ScienceDaily Headlines)
Source: MedWorm: Oral Cancer
Tags: Bisphosphonates, Cancer, double, esophageal, finds, long, Oral, risk, Study, term
Posted in Treatment | No Comments »
Conclusions:
Our in vitro and in vivo data support PGG as a potential drug candidate for breast cancer with novel targeting actions, especially for a triple negative BCa xenograft model. (Source: Breast Cancer Research)
Source: MedWorm: Oral Cancer
Tags: Active, Against, arrest, Breast, Cancer, cells, cyclindependent, growth, human, independently, induces, Inhibitor, Kinase, Negative, Orally, PentaOgalloylbetaDglucose, replicative, Sphase, Triple, xenograft
Posted in Treatment | No Comments »
Conclusions We show here a markedly reduced docetaxel exposure followed by CYP3A induction by, most likely, dexamethasone. Peroral midazolam
seemed not to predict docetaxel exposure. Slow CYP3A-mediated metabolism might predispose patients to adverse events of docetaxel.
Content Type Journal ArticleDOI 10.1007/s00280-010-1426-6Authors
Johanna Hilli, Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itäinen Pitkäkatu 4B, 3rd floor, 20520 Turku, FinlandLiisa Sailas, Department of Oncology, Vaasa Central Hospital, Vaasa, FinlandSirkku Jyrkkiö, Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FinlandSeppo Pyrhönen, Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FinlandKari Laine, …
Source: MedWorm: Oral Cancer
Tags: Activity, Breast, Cancer, CYP3A, docetaxel, exposure, Induction, lowered, NCT01110291, patients, primary
Posted in Treatment | No Comments »
Conclusions S-1 plus docetaxel combination therapy in an outpatient setting provided promising activity with acceptable adverse toxicities.
Content Type Journal ArticleDOI 10.1007/s00280-010-1433-7Authors
Chikara Kunisaki, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanMasazumi Takahashi, Department of Surgery, Yokohama Municipal Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-0062 JapanHirochika Makino, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanTakashi Oshima, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024 JapanShoichi …
Source: MedWorm: Oral Cancer
Tags: Advanced, Biweekly, Cancer, chemotherapy., Combination, docetaxel, FirstLine, Gastric, Phase, Study, Treatment
Posted in Treatment | No Comments »
Nature Reviews Clinical Oncology 7, 482 (2010). doi:10.1038/nrclinonc.2010.126
Author: Rebecca Kirk
Bisphosphonates are commonly prescribed for the treatment of osteoporosis and for the prevention of cancer-induced bone loss. Interest in the potential of bisphosphonates for the prevention of cancer was sparked by a publication last year by Michael Gnant and coworkers. They reported that intravenous adjuvant (Source: Nature Clinical Practice Oncology)
Source: MedWorm: Oral Cancer
Tags: bisphosphonate, Breast, Cancer, Oral, Prevention, Protect, Women
Posted in Treatment | No Comments »
